Mirum Pharmaceuticals (STU:08D) Valuation Rank


STU:08D Mirum Pharmaceuticals Inc STU:08D
51 GF Score
Price €109.30
GF Value €67.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Mirum Pharmaceuticals Valuation Rank Related Terms

STU:08D
51GF Score
Mirum Pharmaceuticals Inc STU:08D
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €109.30 is trading 62.2% above its estimated GF Value™ of €67.40. GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:08D:

  • Valuation Rank:
  • GF Value™: €67.40 vs. price of €109.30 (62.2% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
51GF Score

Get the complete analysis for STU:08D

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€109.30
Price
€67.40
GF Value